Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study

Effect of clinical treatments for metabolic syndrome on albuminuria: a systematic review protocol

Introduction: Metabolic syndrome (MetS) predicts cardiovascular disease, and patients with this condition and type 2 diabetes have increased albuminuria, significantly impacting cardiovascular mortality and kidney disease progression. A considerable number of interventions to control MetS exist and are considered efficient, including the use of medication and changes in lifestyle. However, which approaches are effective in controlling albuminuria remains unclear. This systematic review protocol aims to map in the available literature whether lifestyle, medication, and surgical intervention for MetS have an impact on reducing albuminuria in adult patients. Methods: The Joanna Briggs Institute methodology for systematic reviews will be followed. Cochrane Database of Systematic Reviews, Scopus, Embase, and MEDLINE/PubMed databases will be used. For the Gray Literature, the DART-Europe E-theses Portal. There will be no language restriction. Studies written after 2009 will be included due to the consensus and definition of metabolic syndrome. This review will include studies considering pharmacological and non-pharmacological treatments for controlling albuminuria in patients with MetS. Studies where MetS is described in children and adolescents, animals, pregnant women, and patients with type 1 diabetes will be excluded. First, the selection will be based on reading the title and summary of the texts retrieved in the search strategy, followed by reading the relevant texts in full by two reviewers. After the selection of the studies, the extraction of the data, analysis, and synthesis will be conducted according to the JBI methodology.

Biocrust Research in China: Recent Progress and Application in Land Degradation Control

Desert ecosystems are generally considered lifeless habitats characterised by extreme environmental conditions, yet they are successfully colonised by various biocrust nonvascular communities. A biocrust is not only an important ecosystem engineer and a bioindicator of desert ecological restoration but also plays a vital role in linking surficial abiotic and biotic factors. Thus, extensive research has been conducted on biocrusts in critical dryland zones. However, few studies have been conducted in the vast temperate deserts of China prior to the beginning of this century. We reviewed the research on biocrusts conducted in China since 2000, which firstly focused on the eco-physiological responses of biocrusts to species composition, abiotic stresses, and anthropological disturbances. Further, research on the spatial distributions of biocrusts as well as their succession at different spatial scales, and relationships with vascular plants and soil biomes (especially underlying mechanisms of seed retention, germination, establishment and survival of vascular plants during biocrust succession, and creation of suitable niches and food webs for soil animals and microorganisms) was analysed. Additionally, studies emphasising on the contribution of biocrusts to ecological and hydrological processes in deserts as well as their applications in the cultivation and inoculation of nonvascular plants for land degradation control and ecological restoration were assessed. Finally, recent research on biocrusts was evaluated to propose future emerging research themes and new frontiers.

Fimasartan: A new armament to fight hypertension

Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in pharmacotherapy of hypertension. Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers.